Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism [Yahoo! Finance]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
See our latest analysis for Trevi Therapeutics. Those clinical updates and recent broker commentary come after a mixed price patch, with the share price at US$11.18, a 30 day share price return of a 12.45% decline, a 90 day share price return of a 15.14% gain, and a 1 year total shareholder return of 192.67%, suggesting momentum has been building over a longer stretch. If Trevi's clinical story has caught your attention, it could be a good moment to see what else is happening across healthcare stocks and compare different potential opportunities in the sector. With the stock at US$11.18 and analyst targets clustered around the high teens to low US$20s, the key question is whether Trevi is still trading at a discount or if markets are already pricing in future growth. On a P/B of 7.6x against a last close of US$11.18, Trevi looks richly valued compared with both its industry and closest peers. P/B compares a company's market value to its net assets, which is often used for e
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? [Yahoo! Finance]Yahoo! Finance
- Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.MarketBeat
- Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $19.00 price target on the stock.MarketBeat
- Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare ConferencePR Newswire
- MarketBeat's Top 5 Rated Small-Cap Stocks [Yahoo! Finance]Yahoo! Finance
TRVI
Earnings
- 11/13/25 - Beat
TRVI
Sec Filings
- 1/12/26 - Form 4
- 1/12/26 - Form 3
- 12/5/25 - Form 8-K
- TRVI's page on the SEC website